On 5/22/2012 4:31 PM, Dogman wrote:

Opinion: Misleading Drug Trials

Amgen’s incomplete report on an early major trial of epoetin misled
the medical community about the anemia drug’s risks and benefits—and
helped make Amgen rich.

By Daniel W. Coyne | May 14, 2012

http://the-scientist.com/2012/05/14/...g-drug-trials/

"And if the intent was not to mislead, why not just publish subsequent
articles clarifying the results, especially the quality of life
results? The anemia workgroups that developed the KDOQI guidelines
included one of the 1998 NEJM authors. Why not notify the KDOQI
organization and other workgroup members that they were misreading the
1998 NEJM results? I cannot imagine what Amgen would have done if they
had intended to mislead."

Now, James and Trader would no doubt subscribe this to be incompetence
or merely an unfortunate accident. I, on the other hand, would
subscribe this to GREED.

Incompetence, accident and greed do sometimes rear their ugly head.
But science is self correcting in the long term.


Unless, of course, "increased quality of life" actually means DEATH.